Familial hypercholesterolaemia: identification and management [CG71]
Measuring the use of this guidance
Lipid-modifying drug therapy for a child or young person with FH should usually be considered by the age of 10 years. The decision to defer or offer lipid-modifying drug therapy for a child or young person should take into account:
the age of onset of coronary heart disease within the family, and
the presence of other cardiovascular risk factors, including their LDL-C concentration.
What was measured: The proportion of children with familial hypercholesterolaemia on statins.
Data collection end: November 2014
Number that met the criteria: 111 / 232
Ramaswami U, Cooper J, and Humphries S E. (2017). The UK Paediatric Familial Hypercholesterolaemia Register: Preliminary data. Archives of Disease in Childhood, 102, pp.255-260.